Phio Pharmaceuticals Corp. (PHIO) Institutional Ownership

Ownership Summary

Recent 13F filings as of December 2025 show that 16 institutional investors hold a position in Phio Pharmaceuticals Corp. (NASDAQ:PHIO).

• Phio Pharmaceuticals saw its institutional ownership percentage rose to 9.6% in December 2025 from 5.1% in September 2025.
• The company experienced a 88.44% quarterly change in institutional shares held, alongside an increase of 23.08% in total owners annually.
• A review of institutional activity for Phio Pharmaceuticals shows 12 of 16 filers increasing their positions, while 0 reduced their stake, and 4 remained unchanged.
• The aggregate institutional position in Phio Pharmaceuticals now stands at 353.63K shares as of December 2025, after investors increased their holdings (up by 165.97K shares quarter on quarter which is up 199.59K shares year over year).
• The top institutional stake in Phio Pharmaceuticals as of December 31, 2025 belongs to GEODE CAPITAL MANAGEMENT, LLC, which owns 92.64K shares, or 2.50% of the company.
• Among the most significant buyers of Phio Pharmaceuticals during December 2025 were GEODE CAPITAL MANAGEMENT, LLC (34.73K), NORTHERN TRUST CORP (23.76K), DRW Securities, LLC (22.64K), SUSQUEHANNA INTERNATIONAL GROUP, LLP (20.09K), TWO SIGMA INVESTMENTS, LP (14.49K).
• The top 10 institutional holders of Phio Pharmaceuticals for the quarter ending December 2025 included GEODE CAPITAL MANAGEMENT, LLC (92.64K), VANGUARD GROUP INC (87.63K), Cetera Investment Advisers (42.50K), NORTHERN TRUST CORP (23.76K), DRW Securities, LLC (22.64K), SUSQUEHANNA INTERNATIONAL GROUP, LLP (20.09K), TWO SIGMA INVESTMENTS, LP (14.49K), StoneX Group Inc. (11.83K), Robertson Stephens Wealth Management, LLC (10.80K), CAPTRUST FINANCIAL ADVISORS (10.00K).